HeartWare International Given Consensus Recommendation of “Buy” by Brokerages (NASDAQ:HTWR)
Shares of HeartWare International (NASDAQ:HTWR) have received an average rating of “Buy” from the twelve analysts that are presently covering the company, Analyst Ratings News reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $107.14.
HTWR has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of HeartWare International in a research note on Friday, August 1st. They now have a $125.00 price target on the stock, down previously from $128.00. Separately, analysts at Leerink Swann cut their price target on shares of HeartWare International from $120.00 to $105.00 in a research note on Friday, August 1st. Finally, analysts at Zacks upgraded shares of HeartWare International from a “neutral” rating to an “outperform” rating in a research note on Friday, August 1st. They now have a $105.70 price target on the stock.
Shares of HeartWare International (NASDAQ:HTWR) opened at 79.66 on Monday. HeartWare International has a one year low of $69.31 and a one year high of $105.84. The stock’s 50-day moving average is $87.2 and its 200-day moving average is $91.50. The company’s market cap is $1.353 billion.
HeartWare International (NASDAQ:HTWR) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.74) by $0.45. The company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $67.01 million. On average, analysts predict that HeartWare International will post $-2.30 earnings per share for the current fiscal year.
Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.